CNBX Pharmaceuticals
Cnnabinoid-based Cancer Therapies
StartupCNBX Pharmaceuticals is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2004. Cnnabinoid-based Cancer Therapies. CNBX Pharmaceuticals was founded by Eyal Ballan, Zohar Koren, Itamar Borochov. The company has 1-10 employees.
The company follows a B2B business model. Product stage: Clinical Trial.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- Last RoundUndisclosed
Eyal BallanCo-founder (No longer with the company)
Zohar KorenCo-founder (No longer with the company)
Itamar BorochovCo-founder (No longer with the company)
6 articles covered by sources including www.prnewswire.com.
What does CNBX Pharmaceuticals do?
CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy. CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.
Who founded CNBX Pharmaceuticals?
CNBX Pharmaceuticals was founded in 2004 by Eyal Ballan (Co-founder (No longer with the company)), Zohar Koren (Co-founder (No longer with the company)), Itamar Borochov (Co-founder (No longer with the company)).
What sector is CNBX Pharmaceuticals in?
CNBX Pharmaceuticals operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Medical Cannabis.
Where is CNBX Pharmaceuticals located?
CNBX Pharmaceuticals is based in HaBarzel St 11, Tel Aviv-Yafo, 6971017, Israel. The company also has offices abroad.